Novartis AG launched a lottery-style program to give away doses of its pricey gene therapy for free, drawing criticism from patient groups that say that is an inappropriate way to distribute a lifesaving treatment aimed at babies. Zolgensma, a one-shot cure for a deadly inherited disease whose victims cannot control their muscles, is so far […]
Turkey has long-sought to heal wounds in conflict zones around the world, and with a new locally-produced drug, Ankaferd BloodStopper, it will now be able to do just that. Ankaferd BloodStopper is a coagulant agent touted as Turkey’s first fully domestic medicine.
Bristol-Myers Squibb has finalized its $74 billion acquisition of Celgene Corp., forming an even larger biopharmaceuticals giant, the company announced Wednesday. Regulators signed off on the transaction, which was first announced in January, after Celgene agreed in August to sell its psoriasis drug Otezla to Amgen for $13.4 billion.
Frequent inspections of Indian plants by the US FDA and subsequent observations slow down the growth of pharma exports even as US-China trade war presents huge opportunities for the drug industry, GV Prasad, Chairman
Risks from pharmaceutical residues entering the environment are not being assessed, thereby endangering freshwater ecosystems.
Merck’s Ervebo gets its first regulatory greenlight. A decision from the US Food and Drug Administration is expected in the next few months.
The Standard Operating Procedures (SOPs) have a detailed description level. It has been said that they should be written so that you could take any person from the street and that person would be able do the correct thing by following the SOP.
If you were the chief executive officer of a successful pharmaceutical company would you want to know that your company was meeting and exceeding customer expectations? Do you know who your customers are?
Merck, like many of its Big Pharma peers, is working to focus more on innovative drugs. But as part of that ongoing shift, the company is eliminating 500 positions nationwide.
J&J, which is facing thousands of lawsuits from people who claim its talc products caused cancer, said it had initiated the voluntary recall of one lot of baby powder, produced and shipped in the US in 2018, out of “an abundance of caution”.
